Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | +0.94% | +2.56% | +12.67% |
May. 09 | Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
Apr. 17 | DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 164M 120M |
---|---|---|---|---|---|
Net income 2024 * | -36M -26.4M | Net income 2025 * | -47M -34.47M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.57
x | P/E ratio 2025 * |
-3.69
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Therapeutics Inc.
1 day | +5.32% | ||
1 week | -2.46% | ||
Current month | +25.30% | ||
1 month | +33.76% | ||
3 months | +8.19% | ||
6 months | +33.19% | ||
Current year | +11.62% |
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 3.2 | +0.94% | 2 954 |
24-05-16 | 3.17 | +5.32% | 10,098 |
24-05-15 | 3.01 | -0.33% | 12,225 |
24-05-14 | 3.02 | -5.33% | 24,204 |
24-05-13 | 3.19 | +2.24% | 18,196 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.62% | 120M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.26% | 22.28B | |
-11.90% | 22.41B | |
-5.57% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- DMAC Stock